Heather A. Wakelee, MD
Novel treatments and strategies continue to emerge in the treatment paradigm for patients with EGFR
–positive non–small cell lung cancer (NSCLC), explained Heather Wakelee, MD.
OncLive: Can you highlight some of the latest advances in EGFR-positive lung cancer?
: There is a lot happening in the EGFR space. We now have several first-generation drugs and a couple of second-generation drugs. Third-generation osimertinib has also been FDA approved. Most of the recent data that have been very interesting are the direct comparisons. Until very recently, we went for many, many years without having direct comparisons of different TKIs in the first-line setting.
... to read the full story